Myriad Genetics, Inc. (MYGN) has agreed to sell select operating assets and intellectual property, including the Vectra test, from Myriad Autoimmune's business unit to Labcorp (LH) for $150 million. Myriad expects the deal to close by the end of the third quarter.
Paul Diaz, CEO of Myriad Genetics, said: "While we are strong believers in the future growth prospects for Vectra, this divestiture will allow us to increase operational focus and better execute in our core strategic businesses of Women's Health, Oncology, and Mental Health."
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.